News
Jul 22, 2026
AbstractBackgroundCardiac amyloidosis (CA) is increasingly recognized in clinical practice. Whether a guideline-based large language model can deliver clinician-…
Jul 22, 2026
As AstraZeneca exited the first quarter, initially skeptical analysts were coming around to the potential for the drugmaker to hit its goal of growing sales to $80…
Jul 22, 2026
Royalty Pharma has secured a stake in another transthyretin-mediated (ATTR) amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the…
Jul 22, 2026
AbstractBackground:Transthyretin (TTR) p.Ala45Thr variant is pathogenic, typically associated with cardiomyopathy and peripheral neuropathy. Leptomeningeal and…
Jul 22, 2026
AbstractIntroduction:Cardiac amyloidosis (CA) has been considered a rare disease. However, its prevalence is growing as healthcare practitioners have new, less…
Jul 21, 2026
Most patients with variant transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who received tafamidis through an early access program maintained stable or…
Jul 21, 2026
Cardiac amyloidosis is a serious heart disease that is often diagnosed too late because its symptoms overlap with those of other cardiovascular diseases. Using…
Jul 21, 2026
ABSTRACTBackgroundCardiac amyloidosis, primarily due to immunoglobulin light chain (AL) or transthyretin (ATTR) amyloid, is an increasingly recognized cause of…
Jul 20, 2026
Cardiac involvement is the principal determinant of prognosis in light-chain (AL) amyloidosis. B-type natriuretic peptide (BNP) and N-terminal pro-B-type…
Jul 20, 2026
Significant gaps remain in diagnosing hereditary transthyretin amyloidosis (hATTR) within the Black population, a new study in the Journal of Community Genetics…